

NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING
AGENDA

ROOM: CARLYLE

Delta Chelsea, Toronto, ON

Saturday, May 2nd, 2009

Chair: Dr. Warren Mason
(8:30 a.m. – 12:00 p.m.)

8:30 a.m.	WELCOME AND INTRODUCTIONS	W. Mason
	COMPLETED STUDIES	
8:40 a.m.	CE.3 – Temozolomide plus RT vs RT for GBM → Long-term survivorship update	W. Mason
8:50 a.m.	IND.170 – A Phase I/II study of GW572016 in GBM → Manuscript status	B. Thiessen
	ACTIVE TRIALS	
9:00 a.m.	IND.162 – A Phase I/II study of RAD001c plus Temozolomide in GBM	W. Mason
9:15 a.m.	CE.5 – RT vs Temozolomide for low-grade glioma	W. Mason D. Rheaume
9:45 a.m.	CE.6 – RT vs RT plus Temozolomide for elderly GBM	N. Laperriere J. Perry
10:00 a.m.	COFFEE BREAK	

continued...

FUTURE NCIC PHASE II/III STUDIES

- 10:15 a.m. CEC.1 – A Phase III trial of Radiotherapy with and without concurrent and adjuvant Temozolomide chemotherapy for 1p/19q non-deleted anaplastic gliomas (CATNON Trial) W. Mason
- 10:30 a.m. CEC.2 – Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial) G. Cairncross

IDEAS FOR NEW BRAIN TUMOUR TRIALS

- 11:00 a.m. NCCTG N0574 - St RT with and without WBRT for 1-3 cerebral metastases C. Menard
- 11:15 a.m. Post-operative radiosurgery to the tumor bed following resection of a single metastasis: A Phase III trial. D. Roberge
- 11:30 a.m. Surgery versus radiosurgery for the treatment of single brain metastases. A prospective randomized trial. G. Zadeh
- 11:45 a.m. Report from the NCIC CTG IND meeting W. Mason
- 12:00 p.m. ADJOURN